Concepedia

Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis

S.P. Menting, P.P.M. van Lümig, Anna-Christa Q. de Vries, J.M.P.A. van den Reek, Desirée van der Kleij, E.M.G.J. de Jong, Phyllis I. Spuls, L.L.A. Lecluse

JAMA Dermatology · 2013 · 81 citations · 18 references

DOIFull text

Open access

Abstract

Patients with no ADA formation in the first 24 weeks of treatment have little chance of it in the following 24 weeks. The presence of ADA is strongly correlated with adalimumab concentration and greatly influences clinical response. If ADA is present, dose interval shortening is less useful.

References

18

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Alan Menter, Stephen K. Tyring, Kenneth B. Gordon et al. · Journal of the American Academy of Dermatology · 2007 · 869 citations

, , +7

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Ulrich Mrowietz, Knud Kragballe, Kristian Reich et al. · Archives of Dermatological Research · 2010 · 868 citations · Full text

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

G. M. Bartelds · JAMA · 2011 · 752 citations · Full text

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

J.‐H. Saurat, G Stingl, Louis Dubertret et al. · British Journal of Dermatology · 2007 · 719 citations

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease

Séverine Vermeire, M. Noman, Gert Van Assche et al. · Gut · 2007 · 599 citations · Full text